<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01912560</url>
  </required_header>
  <id_info>
    <org_study_id>CAT-2003-201</org_study_id>
    <nct_id>NCT01912560</nct_id>
  </id_info>
  <brief_title>Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia</brief_title>
  <acronym>PATHWAYS I</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catabasis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catabasis Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of different doses of
      CAT-2003 in patients with hyperlipidemia when CAT-2003 is taken for 4 weeks. The study will
      evaluate effects of CAT-2003 on (1) fasting triglycerides and non-HDL-C in patients with
      moderate hypertriglyceridemia and (2) fasting LDL-C levels in combination with a statin in
      patients with hypercholesterolemia who are on a statin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute and percent change from baseline in plasma triglycerides in patients with hypertriglyceridemia</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute and percent change from baseline in plasma low density lipoprotein-cholesterol in patients with hypercholesterolemia</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute and percent change from baseline in plasma non-high-density lipoprotein cholesterol</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic effects of CAT-2003 on other lipid biomarkers in patients with hyperlipidemia</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>4 weeks</time_frame>
    <description>Safety and tolerability will be assessed for all enrolled patients from the time the patient signs the informed consent through post-treatment follow-up. Safety parameters include physical exam, vital signs, clinical laboratory tests, ECGs and concomitant medications.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Dyslipidemia</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>CAT-2003 or Placebo Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily for 28 days in patients with moderate hypertriglyceridemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAT-2003 or Placebo Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily for 28 days in patients with moderate hypertriglyceridemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAT-2003 or Placebo Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily for 28 days in patients with moderate hypertriglyceridemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAT-2003 or Placebo Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily for 28 days in patients with hypercholesterolemia who are on a statin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAT-2003</intervention_name>
    <arm_group_label>CAT-2003 or Placebo Dose 1</arm_group_label>
    <arm_group_label>CAT-2003 or Placebo Dose 2</arm_group_label>
    <arm_group_label>CAT-2003 or Placebo Dose 3</arm_group_label>
    <arm_group_label>CAT-2003 or Placebo Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>CAT-2003 or Placebo Dose 1</arm_group_label>
    <arm_group_label>CAT-2003 or Placebo Dose 2</arm_group_label>
    <arm_group_label>CAT-2003 or Placebo Dose 3</arm_group_label>
    <arm_group_label>CAT-2003 or Placebo Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statin</intervention_name>
    <description>All patients being treated with a stable dose of a statin prior to enrollment continue on their dosing regimen.</description>
    <arm_group_label>CAT-2003 or Placebo Dose 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 18 and 69 years at Screening

          -  Hypertriglyceridemia (TG ≥ 200 mg/dL and &lt; 500 mg/dL and non-HDL-C ≥ 100 mg/dL and &lt;
             220 mg/dL) OR

          -  Hypercholesterolemia (LDL-C ≥ 100 mg/dL and &lt; 190 mg/dL and TG value &lt; 200 mg/dL) plus
             a stable dose of statin for at least 4 weeks prior to Screening.

          -  Body mass index (BMI) ≤ 45 kg/m2

        Exclusion Criteria:

          -  History of any major cardiovascular event within 6 months of Screening

          -  Type I diabetes mellitus

          -  Any condition that may predispose the patient to secondary hyperlipidemia, such as
             uncontrolled hypothyroidism

          -  Any statin at the highest approved dose

          -  Non-statin lipid-altering drugs other than cholesterol absorption inhibitors.

          -  Active peptic ulcer disease or a history of muscle disease or myopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <zip>35662</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2013</study_first_submitted>
  <study_first_submitted_qc>July 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2013</study_first_posted>
  <disposition_first_submitted>February 24, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>February 24, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 17, 2015</disposition_first_posted>
  <last_update_submitted>July 26, 2016</last_update_submitted>
  <last_update_submitted_qc>July 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

